FDA Approves Sensipar

Sensipar is a first-in-class oral calcimimetic indicated
for the treatment of secondary hyperparathyroidism (secondary HPT)
in chronic kidney disease (CKD) patients on dialysis, and the
treatment of elevated calcium levels (hypercalcemia) in patients
with parathyroid carcinoma.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.